Standout Papers

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): l... 2022 2026 2023 2024169
  1. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (2022)
    Robert J. Motzer, Thomas Powles et al. The Lancet Oncology

Immediate Impact

9 by Nobel laureates 1 from Science/Nature 65 standout
Sub-graph 1 of 22

Citing Papers

Recent Advances in 3D Printing of Smart Scaffolds for Bone Tissue Engineering and Regeneration
2024 Standout
Regulatory mechanisms of PD-1/PD-L1 in cancers
2024 Standout
2 intermediate papers

Works of María T. Bourlon being referenced

Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.
2021
The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials
2020

Author Peers

Author Last Decade Papers Cites
María T. Bourlon 546 386 197 262 79 762
Naveen S. Basappa 566 336 127 291 94 775
Hironori Fukuda 532 428 210 201 89 734
Réza Elaidi 514 447 116 290 33 850
Vanita Noronha 396 443 171 145 96 964
Shaan Dudani 501 398 131 257 48 723
Zbyněk Bortlíček 468 497 67 273 72 897
Aranzazu González del Alba 495 259 93 347 77 834
Sabeen Mekan 407 441 99 256 50 774
Che‐Kai Tsao 350 247 248 154 77 741
Jae Young Joung 551 338 275 225 78 867

All Works

Loading papers...

Rankless by CCL
2026